CHILDHOOD MASTOCYTOSIS NEW DEVELOPMENTS IN DIAGNOSIS AND TREATMENT

CHI775LDHOOD_MASTOCYTOSI775S_NEW_DEVELOPMENTS_IN_DI775AGNOSI775S_AND_TREATMENTKAPAK

CHILDHOOD MASTOCYTOSIS AND PROGNOSIS

Hatice Eke Güngör

Kayseri City Hospital, Department of Pediatric Immunology and Allergy Diseases, Kayseri, Türkiye

Eke Güngör H. Childhood Mastocytosis and Prognosis. In: Özdemir Ö, editor. Childhood Mastocytosis: New Developments in Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.109-116.

ABSTRACT

Mastocytosis is defined by the excessive proliferation and accumulation of mast cells in organs such as the skin, liver, spleen, lymph nodes, gastrointestinal tract, and bone marrow. Cutaneous mastocytosis, which is only presented with skin findings, is usually seen in childhood. The classification of masto- cytosis is crucial, as CM generally has a favorable prognosis, while the prognosis for systemic masto- cytosis can vary widely. Generally, prognosis is good in children and the disease tends to resolve with age. Identifying the type of mastocytosis is crucial for forecasting the disease’s clinical progression and determining the prognosis. Non-advanced mastocytosis includes cutaneous mastocytosis, indolent sys- temic mastocytosis, and smoldering systemic mastocytosis, all of which generally have a stable course and favorable prognosis. Advanced systemic mastocytosis, including aggressive systemic mastocy- tosis, mastocytosis with a hematological neoplasm, and mast cell leukemia, is associated with a poor prognosis. Understanding these differences in biology and prognosis is key for proper management.

Keywords: Mastocytosis; Child; Cutaneous; Systemic; Prognosis

Referanslar

  1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of myeloid neo plasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022:5;140(11):1200-1228. [Crossref]  [PubMed]  [PMC]
  2. Giona F. Pediatric mastocytosis: An update. Mediterr J Hematol Infect Dis. 2021;13(1):e2021069. [Crossref]  [PubMed]  [PMC]
  3. Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A. The international consensus classification of mastocytosis and related entities. Virchows Archiv. 2023;482(1):99-112. [Crossref]  [PubMed]
  4. Khoury JD, Solary E, Abla O, Decamp M, Matthieu Decamp, Luquet I, et al. The 5th edition of the World Health Organization classification of hematolymphoid Tumors: myeloid and histiocytic/ dendritic neoplasms. Leukemia. 2022:36;1703-1719. [Crossref]  [PubMed]  [PMC]
  5. Valent P, Sotlar K, Horny HP, Arock M, Akin C. World Health Organization Classification and Diagnosis of Mastocytosis. Immunol Allergy Clin North Am. 2023;43(4):627-649. [Crossref]  [PubMed]
  6. Lange M, Hartmann K, Carter MC, Siebenhaar F, Alvarez-Twose I, Torrado I, et al. Molecular background, clinical features and management of pediatric mastocytosis: Status 2021. Int J Mol Sci. 2021;22(5).2586. [Crossref]  [PubMed]  [PMC]
  7. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis. The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35-45. [Crossref]  [PubMed]
  8. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;13:5(11):e646. [Crossref]  [PubMed]  [PMC]
  9. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946-956. [Crossref]  [PubMed]  [PMC]
  10. Kibsgaard L, Deleuran M, Flohr C, Langan S, Braae Olesen A, Verstergaard C. How 'benign' is cutaneous mastocytosis? A Danish registry-based matched cohort study. Int J Womens Dermatol. 2020;6:294-300. [Crossref]  [PubMed]  [PMC]
  11. Sandru F, Petca RC, Costescu M, Dumitraşcu MC, Popa A, Petca A, et al. Cutaneous mastocytosis in childhood-Update from the Literature. J Clin Med. 2021;2:10(7):1474. [Crossref]  [PubMed]  [PMC]
  12. Nemat K, Abraham S. Cutaneous mastocytosis in childhood. Allergol Select. 2022;5:6:1-10. [Crossref]  [PubMed]  [PMC]
  13. Middelkamp Hup MA, Heide R, Tank B, Mulder PGH, Oranje AP. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16:115-120. [Crossref]  [PubMed]
  14. Kettlehut B, Metcalfe D. Pediatric mastocytosis. J Invest Dermatol. 1991;96:15-18. [Crossref]  [PubMed]
  15. Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963;87:146-157. [Crossref]  [PubMed]
  16. Sathishkumar D, Balasundaram A, Mathew SM, Mathew L, Thomas M, Balasubramanian P, et al. Clinicopathological profile of childhood onset cutaneous mastocytosis from a tertiary care center in south India. Indian Dermatol Online J. 2021;12:706-713. [Crossref]  [PubMed]  [PMC]
  17. Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, Gutiérrez-Castrellón P, RuizMaldonado R. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18(3):285-290. [Crossref]  [PubMed]
  18. Akoglu G, Erkin G, Cakir B, Boztepe G, Sahin S, Karaduman A, et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol 2006;20:969-973. [Crossref]  [PubMed]
  19. Azana JM, Torrelo A, Mediero IG, Zambrano A. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatric Dermatology. 1994;11:102-106 [Crossref]  [PubMed]
  20. Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7:320-322. [PubMed]
  21. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD, Carter MC. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629-634. [Crossref]  [PubMed]  [PMC]
  22. Giona F. Pediatric Mastocytosis: An Update. Mediterr J Hematol Infect Dis. 2021;13(1): e2021069 [Crossref]  [PubMed]  [PMC]
  23. Chaudhary N, Shapiro N, Bhutada A, Rastogi, S. c-KIT-Positive Fatal Diffuse Cutaneous Mastocytosis With Systemic Manifestations in a Neonate. J Pediatr Hematol Oncol. 2019;41:e338-e340. [Crossref]  [PubMed]
  24. Rydz A, Lange M, Ługowska-Umer H, Sikorska M, Nowicki RJ, Morales-Cabeza C, et al. Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease. Int J Mol Sci. 2024;25(3):1401. [Crossref]  [PubMed]  [PMC]
  25. Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P, et al. Large Maculopapular Cutaneous Lesions Are Associated with Favorable Outcome in Childhood-Onset Mastocytosis. J. Allergy Clin. Immunol. 2015;136:1581-1590.e3. [Crossref]  [PubMed]
  26. Czarny J, Renke J, Zawrocki A, Nowicki RJ, Lange M. Natural Evolution in Pediatric Cutaneous Mastocytosis: 10-year Follow-up. Int J Dermatol. 2021;60:1253-1257. [Crossref]  [PubMed]
  27. Méni C, Bruneau J, Georgin-Lavialle S, Le Sache de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Paediatric Mastocytosis: A Systematic Review of 1747 Cases Br J Dermatol. 2015;172:642-651. [Crossref]  [PubMed]
  28. Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, BenShoshan M. Natural history and treatment of cutaneous and systemic mastocytosis. Postgrad Med. 2017;129(8):896-901. [Crossref]  [PubMed]
  29. Boutista-Quach M, Booth C, Kheradpour A, Zuppan C, Rowsell E, Weiss L. et al. Mast cell sarcoma in an infant: A case report and review of the literature. J Pediatr Hematol Oncol. 2012;35:315-320. [Crossref]  [PubMed]
  30. Zheng Y, Nong L, Liang L, Wang W, Li T. De novo mast cell leukemia without CD25 expression and KIT mutations: A rare case report in a 13-year-old child. Diagn Pathol. 2018;13(1):14. [Crossref]  [PubMed]  [PMC]
  31. Polivka L, Rossignol J, Neuraz A, Condé D, Agopian J, Méni C, et al. Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. J Allergy Clin Immunol Pract. 2021;9(4):16951704.e5. [Crossref]  [PubMed]
  32. Heide R, Zuidema E, Beishuizen A, Den Hollander JC, Gysel DV, Seyger MMB, et al. Clinical Aspects of Diffuse Cutaneous Mastocytosis in Children: Two Variants. Dermatology 2009;219:309-315. [Crossref]  [PubMed]
  33. Lange M, Niedoszytko M, Nedoszytko B, Łata J, Trzeciak M, Biernat W. Diffuse Cutaneous Mastocytosis: Analysis of 10 Cases and a Brief Review of the Literature. J Eur Acad Dermatol Venereol. 2012:26;1565-1571. [Crossref]  [PubMed]
  34. Huang A, Fiadorchanka N, Brar K, Balderacchi JL, Glick SA. In Utero Presentation of Aggressive Systemic Mastocytosis in a Neonate. Br J Dermatol. 2017;177:1439-1441. [Crossref]  [PubMed]
  35. Angus J, Leach IH, Grant J, Ravenscroft JC. Systemic Mastocytosis with Diffuse Cutaneous Involvement and Haematological Disease Presenting in Utero Treated Unsuccessfully with Vincristine. Clin Exp Dermatol. 2008;33:36-39. [Crossref]  [PubMed]
  36. Hannaford R, Rogers M. Presentation of Cutaneous Mastocytosis in 173 Children. Australas J Dermatol. 2001;42:15-21. [Crossref]  [PubMed]
  37. Alvarez-Twose, I, Van-Galván S, Sánchez-Munoz L, Morgado JM, Matito A, Torrelo A, et al. Increased Serum Baseline Tryptase Levels and Extensive Skin Involvement Are Predictors for the Severity of Mast Cell Activation Episodes in Children with Mastocytosis. Allergy 2012:67(6);813-821. [Crossref]  [PubMed]  [PMC]
  38. Heide R, Zuidema E, Beishuizen A, Den Hollander JC, Van Gysel D, Seyger MMB, et al. Clinical Aspects of Diffuse Cutaneous Mastocytosis in Children: Two Variants. Dermatology 2009;219(4):309-315. [Crossref]  [PubMed]
  39. Chan IJ, Tharp MD. Comparison of Lesional Skin C-KIT Mutations with Clinical Phenotype in Patients w i t h Mastocytosis. Clin Exp Dermatol. 2018;43(4):416-422. [Crossref]  [PubMed]
  40. Chaudhary N, Shapiro N, Bhutada A, Rastogi S. C-KIT-Positive Fatal Diffuse Cutaneous Mastocytosis with Systemic Manifestations in a Neonate. J Pediatr Hematol Oncol. 2019;41(5):e338-e340. [Crossref]  [PubMed]
  41. Li Y, Li X, Liu X, Kang L, Liu X. Genotypic and Phenotypic Characteristics of Chinese Neonates with Cutaneous Mastocytosis: A Case Report and Literature Review. J Int Med Res. 2020;48(9):0300060520952621. [Crossref]  [PubMed]  [PMC]
  42. Jiang M, Vadas P. Hereditary alpha-tryptasemia and complete deletion of exon 8 of the c-kit gene in patients with mast cell activation syndrome. Leuk Lymphoma. 2023;64(7):1348-1351. [Crossref]  [PubMed]
  43. Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6(12):e638-e649. [Crossref]  [PubMed]
  44. Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, et al. MARS: Mutation-adjusted risk score for advanced systemic mastocytosis J Clin Oncol. 2019;37(31):28462856. [Crossref]  [PubMed]  [PMC]
  45. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018;2(21):2964-2972. [Crossref]  [PubMed]  [PMC]
  46. Muñoz-González, JI Álvarez-Twose I, Jara-Acevedo M, Henriques A, Viñas E, Prieto C, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2019;134(5):456-468. [Crossref]  [PubMed]
  47. Méni C, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Jais JP, Hadj-Rabia S, Bruneau J, et al. Paediatric mastocytosis: Long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol;179(4):925-932. [Crossref]  [PubMed]
  48. Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol. 2021;8(3):e194-e204. [Crossref]  [PubMed]
  49. Ozdemir O, Savaşan S. Cutaneous Mastocytosis in Childhood. J Clin Pract Res. 2023;45(4):311- 320. [Crossref]
  50. Gurnee EA, Johansen ML, Phung TL, Guo EL, Fong A, Tollefson M, et al. Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms, and associated conditions. Pediatr Dermatol 2021;38(1):159-163. [Crossref]  [PubMed]
  51. Ozdemir O. Management of Cutaneous Mastocytosis during Childhood: Update from the Literature. Hitit Medical Journal 2024;6(1):85-91. [Crossref]